-
Local pharmaceutical companies accelerate the development of TCR-T therapy The market size may exceed 104 billion yuan
Time of Update: 2022-09-08
Drug research and development (Photo source: Pharmaceutical Network) At present, TCR-T therapy mainly targets the solid tumor market and has become a research hotspot internationally, but the global TCR-T therapy industry is still in the experimental research stage .
-
State Food and Drug Administration: Promotion meeting for quality supervision of selected drugs in centralized procurement was held
Time of Update: 2022-09-08
Huang Guo emphasized that the drug regulatory authorities should be brave in their responsibilities, fulfill their responsibilities, pay attention to details, strengthen risk investigation and disposal, and make greater contributions to the overall stability of the country with the stability of drugs in the centralized procurement process.
-
Pharmaceutical companies are accelerating the promotion of "first imitation", and these companies have gained a lot
Time of Update: 2022-09-08
At present, there are fewer enterprises with fusidic acid cream production approvals, and from the perspective of manufacturer competition pattern, Aomei Pharmaceutical has an exclusive market share of more than 70%.
-
The 10 billion ophthalmic drug market has made waves again, and the competition will be more intense!
Time of Update: 2022-09-08
According to industry statistics, since 2022, 5 ophthalmic drugs (15 product specifications) have been approved in China, among which diquafosol sodium eye drops from Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, and hydrochloric acid from Sichuan Heyi Pharmaceutical Lidocaine ophthalmic gel is the first imitation in China .
-
More than half of pharmaceutical companies have achieved performance growth, and the CXO field will benefit in the long run
Time of Update: 2022-09-08
In addition to WuXi AppTec, the net profit attributable to the parent of CXO companies such as Boteng Shares, Gloria Ying, Baicheng Pharmaceutical, and Yaokang Biotech has increased by more than 50% year-on-year.
-
With the enthusiasm of pharmaceutical companies for research and development, the level of children's medication in China is constantly improving
Time of Update: 2022-09-08
For example, since 2008, the Health Commission has invested 600 million yuan through the special project of new drugs to support the research and development of children's drugs and clinical research; The National Children's Medical Center was established, and 23 pediatric medical institutions were united to establish the "China Pediatric Population Drug Clinical Trial Collaboration Network" to promote pediatric clinical trials.
-
The pharmaceutical industry will maintain a high boom development trend for a long time, and these three major sectors deserve attention
Time of Update: 2022-09-08
CXO CXO Judging from the performance of CXO companies that released semi-annual reports, the net profit attributable to the mother of WuXi AppTec, Boteng Shares, Gloria Ying, Baicheng Pharmaceutical, Yaokang Biologics and other companies has exceeded 50% year-on-year growth.
-
131 million! At the end of August, another pharmaceutical company launched a merger and acquisition
Time of Update: 2022-09-08
On August 29, Jiuqiang Bio announced that the company and Xinyu Yuanlang Management Consulting Partnership (hereinafter referred to as "Yuanlang Management") signed an equity transfer agreement on August 29, 2022, and about 131 million yuan was transferred to Fuzhou Maixin Biotechnology Development Co.
-
@ Shanxi people, multiple unit price thousands of yuan drug price reduction!
Time of Update: 2022-09-07
Also on the 28th, Shanxi Pharmaceutical And Device Center issued a notice, according to the application of enterprises, Chengdu Diao Jiuhong Pharmaceutical Factory and other 26 enterprises 56 drug hanging net price adjustment, from the list of points of view, many varieties of price reduction is relatively large, For example, the compound blue palm fruit tablets of Chengdu Diao Jiuhong Pharmaceutical Factory dropped from the original 35.
-
Jiao Hong presided over the symposium on special rectification of drug safety
Time of Update: 2022-09-07
On August 31, Jiao Hong, director of the State Food and Drug Administration, presided over a symposium on special rectification of drug safety in Beijing, listening to the special rectification of dr
-
The vaccine has not changed, why can the nine-valent HPV vaccine be expanded to 9-45 years old
Time of Update: 2022-09-07
” In this regard, the official website of the State Food and Drug Administration has clearly pointed out that the listing of the nine-valent HPV vaccine is based on the urgent clinical needs of drugs and the direct use of overseas clinical data for registration in China .
-
In order to improve and enhance the competitiveness of enterprises, another pharmaceutical company has entered the field of private equity
Time of Update: 2022-09-07
The initial investment amount is 200 million yuan, accounting for 40% of the total subscribed capital contribution .
The initial investment amount is 200 million yuan, accounting for 40% of the total subscribed capital contribution .
-
In the first half of the year, more than 70% of innovative pharmaceutical companies increased their R&D investment!
Time of Update: 2022-09-07
According to the mid-year report of innovative drug companies in 2022, more than 70% of innovative drug companies have increased their R&D investment, and seven companies including BeiGene, Hengrui, Junshi Biopharmaceuticals, China Biopharmaceuticals, CSPC R&D, and Chi-Med have all invested more than 1 billion yuan .
-
Opinions on further strengthening the popularization of science and technology in the new era
Time of Update: 2022-09-07
Recently, the General Office of the CPC Central Committee and the General Office of the State Council issued the "Opinions on Further Strengthening the Popularization of Science and Technology in the
-
In the next five years, the pharmaceutical company plans to introduce a number of innovative drugs from outside
Time of Update: 2022-09-07
However, the research and development cycle of innovative drugs is long, the investment is high, and the risk is large, and it is not easy to eventually succeed, so the License in (license introduction) model has gradually become one of the main means for domestic pharmaceutical companies to supplement their product pipelines at this stage.
-
Focusing on innovation, a large number of pharmaceutical companies ushered in new growth in the first half of the year!
Time of Update: 2022-09-07
It is understood that in the first half of 2022, the sales revenue of Fangsheng Pharmaceutical Yizhi wheat cloth tablets successfully exceeded 100 million, which has exceeded the annual sales revenue of 2021, in addition, the sales revenue of innovative Chinese medicine children's Jingxing cough granules also increased by more than 800% in the same period.
-
The new indications for Merck's nine-valent HPV vaccine have been approved, and the applicable age has been extended to women aged 9-45 years
Time of Update: 2022-09-07
Professor Qiao Youlin said, "Today, the approval of the nine-valent HPV vaccine to expand the age is even more exciting, which will bring more health protection options for women of different ages in China to prevent HPV infection and reduce the risk of related diseases, and further promote China to accelerate the pace of eliminating cervical cancer.
-
The production of medicinal materials has been reduced and the price has soared!
Time of Update: 2022-09-07
As of August 2022, in the quarterly rankings of 331 varieties (involving 431 product specifications), the provinces with a high proportion of rising varieties are mainly concentrated in Jiangsu, Jiangxi, Shaanxi, Sichuan and Zhejiang five provinces, of which Jiangsu, Jiangxi and Zhejiang are more severely affected by high temperature and drought than other provinces because they are at the end of the irrigation area in the Yangtze River Basin, and the price of varieties is rising .
-
Under the pressure of collection and medical insurance, local pharmaceutical companies are actively looking for new growth points
Time of Update: 2022-09-07
In April, ZHAOYAN New Drug, a leading CRO company, announced that on April 28, 2022, the company entered into an equity transfer agreement with Guanfang Group and Xieer Yunkang, which agreed that the company intended to acquire a 60% and 40% equity interest in Weimei Biotechnology for 975 million yuan.
-
The interim report card of 570 pharmaceutical companies was announced, and the pharmaceutical company earned a net profit of over 10 billion yuan
Time of Update: 2022-09-07
For the reason for the surge in performance in the first half of the year, Jiu'an Medical attributed it to the substantial growth in demand for antigen detection kit products in the United States .
